betaSENSE

Detecting neurodegenerative diseases Alzheimers disease and other neurodegenerative diseases undergo a multiple decade long process on a molecular level before their first clinical symptoms arise. In fact, 15-20 years before any clinical symptoms, molecular changes can be observed in the brain through the misfolding of protein biomarkers. With betaSENSEs platform technology, we can precisely monitor and quantify this process in body fluids

Parkinson,als,alzheimer,proteindiagnostik,neurodegenerative krankheiten,and blutbasierte diagnostik

Betasense operates in the Biotechnology research industry.

Betasense's revenue is 11m - 100m

Betasense has 11 - 50 employees.